Showing 2061-2070 of 8586 results for "".
Comorbidities in Alopecia Areata
https://practicaldermatology.com/issues/july-2025/comorbidities-in-alopecia-areata/36507/Alopecia areata (AA) is a chronic, relapsing immune-mediated disorder that causes nonscarring hair loss that can significantly impact a patient’s quality of life.We Are All From Somewhere
https://practicaldermatology.com/issues/july-2025/we-are-all-from-somewhere/36504/Everyone in dermatology has a story about where it all started and where choices were made to lead to the next steps. The common themes are baby steps, gratitude, and not closing the door behind them.Dermatology and CTCL: Recommendations
https://practicaldermatology.com/series/dermwire-tv/dermatology-and-ctcl-recommendations/26798/Larisa J. Geskin, MD, Professor of Dermatology at Columbia University Medical Center, discusses "Time to Act: A Global Patient-Focused Consensus for Improving Care in Cutaneous T-Cell Lymphoma (CTCL)," a global consensus statement from Kyowa Kirin that recommends, among other things, that dermatologClinical Data on Switching to Upadacitinib
https://practicaldermatology.com/programs/practical-dermatology/clinical-data-on-switching-to-upadacitinib/36534/Clinical investigator Christopher Bunick, MD, PhD, discusses results from the LEVEL UP trial among patients who switched from dupilumab to upadacitinib for atopic dermatitis.DermWire TV Extra: Dr. Ruiz on GEP Testing for SCC
https://practicaldermatology.com/topics/skin-of-color/dermwire-tv-extra-dr-ruiz-gep-testing-scc/29497/Emily Ruiz, MD, MPH, FAAD, a Mohs surgeon at Brigham and Women's Hospital and cutaneous oncologist at Dana-Farber Cancer Institute, discusses her recent Future Oncology article, "Predicting adjuvant radiation therapy benefit in cutaneous squamous cell carcinoma with the 40-gene expression profile."Anti-OX40 Ligand Antibody Trials
https://practicaldermatology.com/series/updates-atopic-dermatitis/anti-ox40-ligand-antibody-trials/29531/Lead study author Stephan Weidinger, MD, PhD, Director of the Department of Dermatology and Allergy at the University Hospital Schleswig-Holstein, discusses the phase 2b STREAM-AD trial, evaluating amlitelimab in adult patients with moderate-to-severe atopic dermatitis.UV Risks, Cosentyx Update, ASDS Honorees
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-uv-risks-cosentyx-update-asds-honorees/18623/Teen indoor tanning may be linked with alcohol consumption in the past 30 days, marijuana use, and lifetime use of select illicit drugs, according to findings in JAMA Dermatology. L'Oréal unveiled My UV Patch this month at the Consumer Electronics Show. The stretchable skin sensor, to be introducedFighting for Coverage: Combatting Private Insurance to Get Patients the Drugs They Need
https://practicaldermatology.com/issues/july-2025/fighting-for-coverage/36503/Aside from decreasing reimbursement rates, obtaining prior authorization from private insurance for medications that our patients desperately need to improve their lives, improve their skin conditions, and improve their wellbeing is probably the greatest challenge that dermatologists face today.Emrosi Launched in the US for Rosacea
https://practicaldermatology.com/series/dermwire-tv/emrosi-launched-in-the-us-for-rosacea/33943/In this week's DermwireTV, a new treatment for rosacea is launched in the US; long-term data is presented for tapinarof 1% cream for atopic dermatitis; and in our C-Suite Chats segment, we speak with the CEO and Co-Founder of Mama Sol.I Came In Like a Wrecking Ball
https://practicaldermatology.com/issues/practicaldermatology-com-march-2025/i-came-in-like-a-wrecking-ball/33162/I have to start by warning you, dear reader, that I am writing my first editorial for Practical Dermatology immediately after typing up four appeal letters to insurance companies.